Skip to main content
INTELLIPHARMACEUTICS INTERNATIONAL INC. logo

INTELLIPHARMACEUTICS INTERNATIONAL INC. — Investor Relations & Filings

Ticker · IPCIh ISIN · CA4581733090 LEI · 529900G23JHRE3XDSC03 TSX Manufacturing
Open in API
Filings indexed 381 across all filing types
Latest filing 2024-06-14 Regulatory Filings
Country CA Canada
Listing TSX IPCIh

About INTELLIPHARMACEUTICS INTERNATIONAL INC.

http://www.intellipharmaceutics.com

Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development, manufacture, and commercialization of novel and generic controlled-release and targeted pharmaceutical products. The company utilizes its proprietary controlled-release drug delivery technology, including the patented Hypermatrix platform, for the development of enhanced drug formulations.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Intellipharmaceutics International Inc. will be downgraded from the OTCQB market to the OTC Expert Market due to the company's failure to file its Form 20-F for the fiscal year ended November 30, 2023. It also references a cease trade order issued by the Ontario Securities Commission for failure to file annual audited financial statements and related documents. The document does not contain any actual financial statements or detailed financial data; rather, it is an announcement about regulatory and market status changes related to the company's filings. The document length is 5371 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about filing defaults and market status changes, not the actual annual report or financial statements themselves.
2024-06-14 English
Other.pdf
Regulatory Filings
2023-12-06 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a consent letter from a qualified person regarding a Management Information Circular dated October 13, 2023. It references a technical report and consents to the inclusion of information from that report in the Circular. The document is short (1997 characters) and serves as an expert consent related to a proxy or management circular, not the circular itself or a financial report. This type of document is best classified as a Regulatory Filing (RNS) because it is a regulatory submission related to the circular but does not contain the circular or technical report itself.
2023-10-17 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled '2023 Third Quarter Management Discussion and Analysis' and contains detailed management discussion and analysis of financial condition and results of operations for the three and nine months ended August 31, 2023. It references condensed unaudited interim consolidated financial statements and discusses forward-looking statements, risks, and corporate developments. The content is substantive and includes financial analysis and operational commentary for a quarterly period, which aligns with the characteristics of an Interim / Quarterly Report (IR). The document is approximately 15,000 characters, indicating it is a full report rather than a brief announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). 9M 2023
2023-10-17 English
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109F2 Certification of Interim Filings by the Acting CFO of Intellipharmaceutics International Inc. It certifies the review and fair presentation of interim financial statements and interim MD&A for the period ended August 31, 2023. The content is primarily an officer certification regarding the interim filings, controls, and procedures, without containing actual financial data or substantive financial analysis. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than as an Interim Report (IR). The document length is 3703 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2023-10-17 English
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification under FORM 52-109F2 titled 'CERTIFICATION OF INTERIM FILINGS' by the CEO of Intellipharmaceutics International Inc. It certifies the review and fair presentation of interim financial statements and interim MD&A for the period ended August 31, 2023. The content is primarily an officer certification regarding the interim filings, controls, and procedures, without containing actual financial data or substantive financial analysis. According to the CERTIFICATION RULE, such documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is 3655 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2023-10-17 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.